Evidence map›Paper›PMID 40404705›Full record

ArticleScientific reports2025

First-in-human dosimetry and safety evaluation of

Samaneh Zolghadri, Mohsen Bakhshi Kashi, Nasim Vahidfar, Saeed Farzanefar, Arezou Karimian, Mohammad Hossein Mohammadi Ashnani, Hassan Yousefnia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Samaneh ZolghadriRadiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran.
Mohsen Bakhshi KashiDepartment of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Nasim VahidfarDepartment of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Saeed FarzanefarDepartment of Nuclear Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Arezou KarimianRadiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran.
Mohammad Hossein Mohammadi AshnaniDepartment of Environmental Science and Engineering, Faculty of Agriculture and Environment, Arak University, Arak, Iran.
Hassan YousefniaRadiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, 14155-1339, Iran. hyousefnia@aeoi.org.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melanoma remains one of the leading causes of cancer-related mortality worldwide, necessitating advanced imaging techniques for early and accurate detection. This study assesses the dosimetry, safety, and imaging performance of a novel

Indexed as

alpha-MSHGallium RadioisotopesMelanomaPositron Emission Tomography Computed TomographyRadiopharmaceuticalsAdultAgedFemaleHumansMaleMiddle AgedPositron-Emission TomographyProspective StudiesRadiometryReceptor, Melanocortin, Type 1Tissue Distributionalpha-MSHGallium RadioisotopesRadiopharmaceuticalsReceptor, Melanocortin, Type 1

Identifiers

PMID40404705
PMCPMC12098654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.